Laboratory parameters in 111 TMA patients
| . | TTP (n = 66) . | HUS (n = 45) . | P* . |
|---|---|---|---|
| Hemolytic anemia | 66 (100%) | 45 (100%) | NS |
| Hemoglobin (N: 12-16 g/dL) | 7.2 ± 1.5 (4.7-10.3) | 8.8 ± 1.8 (5.3-11.8) | .01 |
| Schistocytes (percent of erythrocytes) | 4.0 ± 3.0 (0-18) | 2.0 ± 1.4 (0-4) | NS |
| Thrombocytopenia | 62 (94%) | 27 (60%) | .005 |
| Platelet count (N: 150-400 × 109/L) | 35 ± 27 (5-178) | 95 ± 60 (3-272) | .002 |
| Acute anuric renal failure | 1 (1.5%) | 44 (98%) | < .0001 |
| Creatinine (N: 40-110 μmol/L) | 162 ± 140 (54-700) | 360 ± 207 (120-800) | .001 |
| vWF antigen (N: 50-150 IU/dL) | 230 ± 94 (70-540) | 241 ± 156 (94-727) | NS |
| vWF multimers | |||
| LMW (N: 28%-45%) | 39 ± 13 (26-68) | 40 ± 12 (13-63) | NS |
| IMW (N: 34%-45%) | 32 ± 5 (23-44) | 33 ± 4 (28-42) | NS |
| HMW (N: 20%-36%) | 25 ± 6 (5-44) | 25 ± 8 (4-52) | NS |
| UL (N: 0%) | 5 ± 4 (0-18) | 5 ± 4 (0-16) | NS |
| Decreased vWF-cleaving protease | 59 (89%) | 6 (13%) | < .0001 |
| Inhibitor to vWF-protease† | 30 (51%) | 0 (0%) | < .0001 |
| . | TTP (n = 66) . | HUS (n = 45) . | P* . |
|---|---|---|---|
| Hemolytic anemia | 66 (100%) | 45 (100%) | NS |
| Hemoglobin (N: 12-16 g/dL) | 7.2 ± 1.5 (4.7-10.3) | 8.8 ± 1.8 (5.3-11.8) | .01 |
| Schistocytes (percent of erythrocytes) | 4.0 ± 3.0 (0-18) | 2.0 ± 1.4 (0-4) | NS |
| Thrombocytopenia | 62 (94%) | 27 (60%) | .005 |
| Platelet count (N: 150-400 × 109/L) | 35 ± 27 (5-178) | 95 ± 60 (3-272) | .002 |
| Acute anuric renal failure | 1 (1.5%) | 44 (98%) | < .0001 |
| Creatinine (N: 40-110 μmol/L) | 162 ± 140 (54-700) | 360 ± 207 (120-800) | .001 |
| vWF antigen (N: 50-150 IU/dL) | 230 ± 94 (70-540) | 241 ± 156 (94-727) | NS |
| vWF multimers | |||
| LMW (N: 28%-45%) | 39 ± 13 (26-68) | 40 ± 12 (13-63) | NS |
| IMW (N: 34%-45%) | 32 ± 5 (23-44) | 33 ± 4 (28-42) | NS |
| HMW (N: 20%-36%) | 25 ± 6 (5-44) | 25 ± 8 (4-52) | NS |
| UL (N: 0%) | 5 ± 4 (0-18) | 5 ± 4 (0-16) | NS |
| Decreased vWF-cleaving protease | 59 (89%) | 6 (13%) | < .0001 |
| Inhibitor to vWF-protease† | 30 (51%) | 0 (0%) | < .0001 |
Continuous variables are expressed as mean ± SD; extreme values are between brackets. Categorical variables are given as numbers and percentage of cases.
N indicates normal (value); NS, not significant.
Comparisons between the TTP group and the HUS were performed using a χ2 test for categorical variables and an independent sample t test for continuous variables.
The percentage of patients with an inhibitor is calculated among patients with a vWF-protease deficiency.